Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma

被引：0

作者：

Vodanovic, Ivana Dora ^{[1
]}

Nekic, Anja Barac ^{[1
]}

Sambula, Lana ^{[2
]}

Tomsic, Karin Zibar ^{[1
]}

Dusek, Tina ^{[1
,3
]}

Kastelan, Darko ^{[1
,3
]}

机构：

[1] Univ Hosp Ctr Zagreb, Dept Endocrinol, Kispaticeva 12, Zagreb 10000, Croatia

[2] Gen Hosp Tomislav Bardek, Dept Nephrol Endocrinol & Diabetol, Koprivnica, Croatia

[3] Univ Zagreb, Sch Med, Zagreb, Croatia

来源：

ENDOCRINE RESEARCH | 2025年 / 50卷 / 01期

关键词：

Adjuvant treatment; adrenal insufficiency; adrenocortical carcinoma; adverse event; hydrocortisone replacement; mitotane; EUROPEAN NETWORK; PLASMA;

D O I：

10.1080/07435800.2024.2402311

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundMitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events.MethodsA retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane.ResultsMitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events.ConclusionCareful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.

引用

页码：50 / 56

页数：7

共 50 条

[41] A Review on Mitotane: A Target Therapy in Adrenocortical Carcinoma
Flauto, Fabiano
De Martino, Maria Cristina
Vitiello, Chiara
Pivonello, Rosario
Colao, Annamaria
Damiano, Vincenzo
CANCERS, 2024, 16 (23)
[42] Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis
Tang, Yongquan
Liu, Zhihong
Zou, Zijun
Liang, Jiayu
Lu, Yiping
Zhu, Yuchun
BIOMED RESEARCH INTERNATIONAL, 2018, 2018
[43] Metastatic Adrenocortical Carcinoma With a Prolonged Response to Mitotane
Pal, Sumanta K.
Gartrell, Benjamin
Olsson, Carl A.
Stein, C. A.
ONCOLOGY-NEW YORK, 2014, 28 (07): : 624 - +
[44] Mitotane in adrenocortical carcinoma: a profile of its use
Matt Shirley
Drugs & Therapy Perspectives, 2022, 38 : 508 - 519
[45] Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma
Megerle, Felix
Herrmann, Wiebke
Schloetelburg, Wiebke
Ronchi, Cristina L.
Pulzer, Alina
Quinkler, Marcus
Beuschlein, Felix
Hahner, Stefanie
Kroiss, Matthias
Fassnacht, Martin
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (04): : 1686 - 1695
[46] Mitotane in adrenocortical carcinoma: a profile of its use
Shirley, Matt
DRUGS & THERAPY PERSPECTIVES, 2022, 38 (12) : 508 - 519
[47] Adjuvant Mitotane for Adrenocortical Cancer-Working through Uncertainty
Terzolo, M.
Fassnacht, M.
Ciccone, G.
Allolio, B.
Berruti, A.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (06): : 1879 - 1880
[48] Adrenocortical carcinoma:: Surgery and mitotane for treatment and steroid profiles for follow-up
Khorram-Manesh, A
Ahlman, H
Jansson, S
Wängberg, B
Nilsson, O
Jakobsson, CE
Eliasson, B
Lindstedt, S
Tisell, LE
WORLD JOURNAL OF SURGERY, 1998, 22 (06) : 605 - 612
[49] IMPACT OF ADJUVANT MITOTANE ON THE CLINICAL COURSE OF PATIENTS WITH ADRENOCORTICAL CANCER
KASPERLIKZALUSKA, AA
MIGDAKSKA, B
MAKOWSKA, A
CANCER, 1994, 73 (05) : 1533 - 1534
[50] Adrenocortical Carcinoma: Surgery and Mitotane for Treatment and Steroid Profiles for Follow-up
A. Khorram-Manesh
H. Ahlman
S. Jansson
B. Wängberg
O. Nilsson
C.E. Jakobsson
B. Eliasson
S. Lindstedt
L.E. Tisell
World Journal of Surgery, 1998, 22 : 605 - 612

← 1 2 3 4 5 →